Table 1—

Outcome of first-line platinum-based combination chemotherapy phase III trials in extensive-stage small cell lung cancer

	Year	Subjects n	Response %		Survival		Toxicity CTC 3/4 %				[Ref.]
			OR	CR	Median months	At 1 yr %	NP	Anaemia	TP	Other
Cisplatin–etoposide	1985	20	88	29	9.1	30	18				8
Cisplatin–etoposide	1992	159	61	10	8.6	30	70	35	13	6^#	9
Cisplatin–irinotecan (JCOG 9511)	2002	154	84	3	12.8	58	65	27	5	16^¶	18
Cisplatin–irinotecan	2006	331	48		9.3	35	36	5	4	21^¶	19
Carboplatin–irinotecan	2008	209		17	8.5	34	33	5	15	11^¶	20
Cisplatin–irinotecan (S0124)	2008	671	59	4	9.7	39	33	6	4	19^¶	21
Cisplatin–epirubicin	2004	195	74		10.9		42				22
Cisplatin–topotecan (oral)	2006	784	63	6	10.0	31	59	38	38		23
Cisplatin–topotecan (intravenous)	2008	795	55	10	10.3	40	36	12	19		24
Carboplatin–pemetrexed	2008	733	25		7.3		9	10	10		25
Cisplatin–etoposide–paclitaxel	2005	587	75	16	10.6	38	44	19	22		26
Cisplatin–etoposide–ifosfamide	1995	171	73	21	9.0	36	52	52	35		27
Cisplatin–etoposide–cyclophosphamide–epirubicin	2001	226	76	21	10.5	40	99	51	78	22⁺	28

OR: overall response; CR: complete response; CTC: common toxicity criteria; NP: neutropenia; TP: thrombocytopenia; JCOG: Japanese Clinical Oncology Group. ^#: nausea/vomiting; ^¶ diarrhoea; ⁺: infections.